Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the impact of LACTIN-V, a vaginally administered live
biotherapeutic product (LBP) that contains the human L. crispatus CTV-05 strain, on the
vaginal microbiome of Lactobacillus-deficient young women in the South African FRESH study
who are at high risk for HIV acquisition.
Phase:
Phase 2
Details
Lead Sponsor:
Osel, Inc.
Collaborators:
Aurum Institute Harvard University Health Systems Trust University of California, San Francisco University of KwaZulu